CARsgen Therapeutics Holdings Limited (HKG:2171)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
14.40
+0.40 (2.86%)
Feb 13, 2026, 4:08 PM HKT
Market Cap7.78B +36.2%
Revenue (ttm)92.10M +1,225.6%
Net Income-572.06M
EPS-1.04
Shares Out555.80M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume707,500
Average Volume1,430,769
Open13.93
Previous Close14.00
Day's Range13.80 - 14.40
52-Week Range9.44 - 25.60
Beta0.45
RSI43.89
Earnings DateMar 18, 2026

About HKG:2171

CARsgen Therapeutics Holdings Limited, an investment holding company, engages in discovering, developing, and commercializing chimeric antigen receptor T (CAR-T) cell therapies for the treatment of hematological malignancies, solid tumors, and autoimmune diseases in China. Its products include CT053 for the treatment of relapsed/refractory multiple myeloma (R/R MM). The company is also developing autologous CAR-T product candidates, including CT041, which targets Claudin 18.2, is in phase II/III clinical trial for gastric/gastroesophageal junct... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2014
Employees 371
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2171
Full Company Profile

Financial Performance

Financial numbers in CNY Financial Statements